Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ilaprazole · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Ilaprazole 5 mg QD | EXPERIMENTAL | - |
| Ilaprazole 20 mg QD | EXPERIMENTAL | - |
| Ilaprazole 40 mg QD | EXPERIMENTAL | - |
| Lansoprazole 30 mg QD | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ilaprazole | DRUG | Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks. |
| Lansoprazole | DRUG | Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks. |
Inclusion Criteria: * Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D). Exclusion Criteria: * Evidence of uncontrolled, clinically significant systemic disease; acquired immunodeficiency syndrome (AIDs); a condit...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tezepelumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | dupilumab |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | PHASE2 | Vonoprazan |
| Eupraxia Pharmaceuticals, Inc. | EPRX | 1 | PHASE1 | EP-104GI |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Dupilumab |
| Smith & Nephew plc Sponsored ADR | SNN | 1 | - | Undisclosed |
Ilaprazole is an investigational small molecule being studied for the treatment of esophagitis, specifically erosive esophagitis. It is a gastrointestinal therapeutic agent under clinical development, though it is not yet approved and remains in clinical trials.
Ilaprazole is being developed by Takeda Pharmaceutical Company Limited, a company listed on the stock exchange under the ticker TAK. The drug is currently in Phase 2 clinical development for the treatment of esophagitis.
Ilaprazole is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for treating esophagitis.
Ilaprazole has one completed clinical trial, identified as NCT00471094. This Phase 2 study evaluated the safety and efficacy of Ilaprazole at doses of 5, 20, and 40 mg once daily compared to Lansoprazole 30 mg once daily for healing erosive esophagitis. The trial enrolled 831 participants in the United States.
Ilaprazole is a distinct investigational drug and is not known to be the same as any other approved medication. It is being studied as a potential treatment for esophagitis, but no alternative names have been established for this compound.